Background: Tumor necrosis factor (TNF)-
Two of the studies analyzed rates of switching between TNF blockers [10, 11] , and others focused on treatment persistence [12] [13] [14] [15] [16] [17] [18] [19] . None of the studies analyzed rates of restarting the index TNF blocker after a treatment gap. Additionally, one study included patients with RA, PsA, or AS [19] , and others only included patients with RA [10] [11] [12] [13] [14] [15] [16] [17] [18] . For medications with several shared indications, such as etanercept, adalimumab, and infliximab, it is important to consider treatment patterns across conditions, particularly because there is evidence that treatment patterns may differ by condition [20] . Additionally, guidelines for the use of TNF blockers in the treatment of RA [21] , PsO [22] , PsA [23] , and AS [24] 
METHODS

Data Source
This retrospective analysis used administrative Revision, Clinical Modification (ICD-9-CM) diagnosis codes for more than one of these conditions were not included in this report.
INTRODUCTION
The index date needed to occur within the identification period, which began on the first month by which all three TNF blockers had been approved for use in patients with that condition. (1) 12 (1) a Prescribing physician specialty was defined using the claim nearest the index claim. The "other" category includes physician not elsewhere classified. If a physician practiced in a multi-physician specialty then the claim was often classified as not elsewhere classified and hence was classified as "other" in this analysis. The patients in the "other" category may have seen a rheumatologist at another time, just not during the visit closest to the index event
RESULTS
The study criteria were met in 8,454 patients who newly initiated TNF blocker treatment in the study period. Among patients with RA, PsO, PsA, and AS, the mean (SD) age at baseline was 50 (10), 44 (11), 48 (10), and 43 (12) Among patients with PsO (Table 2) , treatment patterns in the first year after starting etanercept, adalimumab, or infliximab treatment, respectively, were: persistence, 22%, 33%, 36%;
restarting initial TNF blocker after a ≥45-day treatment gap, 32%, 24%, and 9%; switch to a different biologic of interest, 7%, 6%, and 9%;
and stop (≥45-day treatment gap with no restart or switch), 38%, 37%, and 45%. Thus, combined rates of either persistence or restarting after a treatment gap among patients with PsO were 54%, 57%, and 45% for etanercept, adalimumab, and infliximab, respectively.
Among patients with PsA (Table 2) , treatment patterns in the first year after starting etanercept, adalimumab, or infliximab treatment, respectively, were: persistence, 47%, 53%, 56%;
restarting initial TNF blocker after a ≥45-day treatment gap, 29%, 17%, and 17%; switch to a different biologic of interest, 10%, 11%, and 10%; and stop (≥45-day treatment gap with no restart or switch), 14%, 19%, and 17%. Thus, the combined rates of either persistence or restarting after a treatment gap among patients with PsA were 76%, 70%, and 73% for etanercept, adalimumab, and infliximab, respectively.
Among patients with AS (Table 2) , treatment patterns in the first year after starting etanercept, adalimumab, or infliximab treatment, respectively, were: persistence, 48%, 34%, 41%;
restarting initial TNF blocker after a ≥45-day treatment gap, 16%, 20%, and 15%; switch to a different biologic of interest, 8%, 11%, and 13%;
and stop (≥45-day treatment gap with no restart or switch), 28%, 35%, and 30%. Thus, combined rates of either persistence or restarting after a treatment gap among patients with AS were 64%, 54%, and 56% for etanercept, adalimumab, and infliximab, respectively. Table 3 
